Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection

Jeffrey A. Anderson, Hongyu Jiang, Xiao Ding, Leslie Anne Petch Lee, Terri Journigan, Susan A. Fiscus, Richard Haubrich, David Katzenstein, Ronald Swanstrom, Roy M. Gulick

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

This study compared the role of genotypic susceptibility scores (GSS) as a predictor of virologic response in a group (n = 234) of HIV-infected, protease inhibitor (PI)-experienced subjects. Two scoring methods [discrete genotypic susceptibility score (dGSS) and continuous genotypic susceptibility score (cGSS)] were developed. Each drug in the subject's regimen was given a binary susceptibility score using Stanford inferred drug resistance scores to calculate the dGSS. In contrast to the dGSS, the cGSS model was designed to reflect partial susceptibility to a drug. Both GSS were independent predictors of week 16 virologic response. We also compared the GSS to a phenotypic susceptibility score (PSS) model on a subset of subjects that had both GSS and PSS performed, and found that both models were predictive of virologic response. Genotypic analyses at enrollment showed that subjects who were virologic nonresponders at week 16 revealed enrichment of several mutated codons associated with nucleoside reverse transcriptase inhibitors (NRTI) (codons 67, 69, 70, 118, 215, and 219) or PI resistance (codons 10, 24, 71, 73, and 88) compared to subjects who were virologic responders. Regression analyses revealed that protease mutations at codons 24 and 90 were most predictive of poor virologic response, whereas mutations at 82 were associated with enhanced virologic response. Certain NNRTI-associated mutations, such as K103N, were rapidly selected in the absence of NRTIs. These data indicate that GSS may be a useful tool in selecting drug regimens in HIV-1-infected subjects to maximize virologic response and improve treatment outcomes.

Original languageEnglish (US)
Pages (from-to)685-694
Number of pages10
JournalAIDS Research and Human Retroviruses
Volume24
Issue number5
DOIs
StatePublished - May 1 2008
Externally publishedYes

Fingerprint

Codon
HIV Infections
HIV-1
RNA
Mutation
Pharmaceutical Preparations
HIV Protease Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Nucleosides
Drug Resistance
Peptide Hydrolases
Research Design
Regression Analysis

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Anderson, J. A., Jiang, H., Ding, X., Petch Lee, L. A., Journigan, T., Fiscus, S. A., ... Gulick, R. M. (2008). Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Research and Human Retroviruses, 24(5), 685-694. https://doi.org/10.1089/aid.2007.0127

Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. / Anderson, Jeffrey A.; Jiang, Hongyu; Ding, Xiao; Petch Lee, Leslie Anne; Journigan, Terri; Fiscus, Susan A.; Haubrich, Richard; Katzenstein, David; Swanstrom, Ronald; Gulick, Roy M.

In: AIDS Research and Human Retroviruses, Vol. 24, No. 5, 01.05.2008, p. 685-694.

Research output: Contribution to journalArticle

Anderson, JA, Jiang, H, Ding, X, Petch Lee, LA, Journigan, T, Fiscus, SA, Haubrich, R, Katzenstein, D, Swanstrom, R & Gulick, RM 2008, 'Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection', AIDS Research and Human Retroviruses, vol. 24, no. 5, pp. 685-694. https://doi.org/10.1089/aid.2007.0127
Anderson, Jeffrey A. ; Jiang, Hongyu ; Ding, Xiao ; Petch Lee, Leslie Anne ; Journigan, Terri ; Fiscus, Susan A. ; Haubrich, Richard ; Katzenstein, David ; Swanstrom, Ronald ; Gulick, Roy M. / Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. In: AIDS Research and Human Retroviruses. 2008 ; Vol. 24, No. 5. pp. 685-694.
@article{50973f32477d457894eafb7433148a8f,
title = "Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection",
abstract = "This study compared the role of genotypic susceptibility scores (GSS) as a predictor of virologic response in a group (n = 234) of HIV-infected, protease inhibitor (PI)-experienced subjects. Two scoring methods [discrete genotypic susceptibility score (dGSS) and continuous genotypic susceptibility score (cGSS)] were developed. Each drug in the subject's regimen was given a binary susceptibility score using Stanford inferred drug resistance scores to calculate the dGSS. In contrast to the dGSS, the cGSS model was designed to reflect partial susceptibility to a drug. Both GSS were independent predictors of week 16 virologic response. We also compared the GSS to a phenotypic susceptibility score (PSS) model on a subset of subjects that had both GSS and PSS performed, and found that both models were predictive of virologic response. Genotypic analyses at enrollment showed that subjects who were virologic nonresponders at week 16 revealed enrichment of several mutated codons associated with nucleoside reverse transcriptase inhibitors (NRTI) (codons 67, 69, 70, 118, 215, and 219) or PI resistance (codons 10, 24, 71, 73, and 88) compared to subjects who were virologic responders. Regression analyses revealed that protease mutations at codons 24 and 90 were most predictive of poor virologic response, whereas mutations at 82 were associated with enhanced virologic response. Certain NNRTI-associated mutations, such as K103N, were rapidly selected in the absence of NRTIs. These data indicate that GSS may be a useful tool in selecting drug regimens in HIV-1-infected subjects to maximize virologic response and improve treatment outcomes.",
author = "Anderson, {Jeffrey A.} and Hongyu Jiang and Xiao Ding and {Petch Lee}, {Leslie Anne} and Terri Journigan and Fiscus, {Susan A.} and Richard Haubrich and David Katzenstein and Ronald Swanstrom and Gulick, {Roy M.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1089/aid.2007.0127",
language = "English (US)",
volume = "24",
pages = "685--694",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection

AU - Anderson, Jeffrey A.

AU - Jiang, Hongyu

AU - Ding, Xiao

AU - Petch Lee, Leslie Anne

AU - Journigan, Terri

AU - Fiscus, Susan A.

AU - Haubrich, Richard

AU - Katzenstein, David

AU - Swanstrom, Ronald

AU - Gulick, Roy M.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - This study compared the role of genotypic susceptibility scores (GSS) as a predictor of virologic response in a group (n = 234) of HIV-infected, protease inhibitor (PI)-experienced subjects. Two scoring methods [discrete genotypic susceptibility score (dGSS) and continuous genotypic susceptibility score (cGSS)] were developed. Each drug in the subject's regimen was given a binary susceptibility score using Stanford inferred drug resistance scores to calculate the dGSS. In contrast to the dGSS, the cGSS model was designed to reflect partial susceptibility to a drug. Both GSS were independent predictors of week 16 virologic response. We also compared the GSS to a phenotypic susceptibility score (PSS) model on a subset of subjects that had both GSS and PSS performed, and found that both models were predictive of virologic response. Genotypic analyses at enrollment showed that subjects who were virologic nonresponders at week 16 revealed enrichment of several mutated codons associated with nucleoside reverse transcriptase inhibitors (NRTI) (codons 67, 69, 70, 118, 215, and 219) or PI resistance (codons 10, 24, 71, 73, and 88) compared to subjects who were virologic responders. Regression analyses revealed that protease mutations at codons 24 and 90 were most predictive of poor virologic response, whereas mutations at 82 were associated with enhanced virologic response. Certain NNRTI-associated mutations, such as K103N, were rapidly selected in the absence of NRTIs. These data indicate that GSS may be a useful tool in selecting drug regimens in HIV-1-infected subjects to maximize virologic response and improve treatment outcomes.

AB - This study compared the role of genotypic susceptibility scores (GSS) as a predictor of virologic response in a group (n = 234) of HIV-infected, protease inhibitor (PI)-experienced subjects. Two scoring methods [discrete genotypic susceptibility score (dGSS) and continuous genotypic susceptibility score (cGSS)] were developed. Each drug in the subject's regimen was given a binary susceptibility score using Stanford inferred drug resistance scores to calculate the dGSS. In contrast to the dGSS, the cGSS model was designed to reflect partial susceptibility to a drug. Both GSS were independent predictors of week 16 virologic response. We also compared the GSS to a phenotypic susceptibility score (PSS) model on a subset of subjects that had both GSS and PSS performed, and found that both models were predictive of virologic response. Genotypic analyses at enrollment showed that subjects who were virologic nonresponders at week 16 revealed enrichment of several mutated codons associated with nucleoside reverse transcriptase inhibitors (NRTI) (codons 67, 69, 70, 118, 215, and 219) or PI resistance (codons 10, 24, 71, 73, and 88) compared to subjects who were virologic responders. Regression analyses revealed that protease mutations at codons 24 and 90 were most predictive of poor virologic response, whereas mutations at 82 were associated with enhanced virologic response. Certain NNRTI-associated mutations, such as K103N, were rapidly selected in the absence of NRTIs. These data indicate that GSS may be a useful tool in selecting drug regimens in HIV-1-infected subjects to maximize virologic response and improve treatment outcomes.

UR - http://www.scopus.com/inward/record.url?scp=44349161109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44349161109&partnerID=8YFLogxK

U2 - 10.1089/aid.2007.0127

DO - 10.1089/aid.2007.0127

M3 - Article

C2 - 18462083

AN - SCOPUS:44349161109

VL - 24

SP - 685

EP - 694

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 5

ER -